ERK2-mediated phosphorylation of ZEB1 at S322 enhances PD-L1 expression and EMT, leading to pancreatic cancer progression
SPC induces ZEB1 phosphorylation, with ERK2, rather than ERK1, targeting the S322 site. Inhibiting S322 phosphorylation mitigates EMT, PD-L1 expression, and progression of pancreatic cancer. The phosphoS322 detection antibody might be a valuable tool for predicting pancreatic cancer prognosis. These findings implicate ERK2 as a potential therapeutic target for pancreatic cancer and highlight phosphoZEB1 as a valuable prognostic marker.
Authors
- Jae Gal Shim
- Tuan Minh Nguyen (ORCID: https://orcid.org/0000-0001-6215-8266)
- Gyeoung-Jin Kang (ORCID: https://orcid.org/0000-0003-0646-9187)
- Seung Hyun Oh (ORCID: https://orcid.org/0000-0003-3678-2772)
- Ki Taek Nam (ORCID: https://orcid.org/0000-0001-5292-1280)
- Yong Yun Kim
- Eun Ji Kim (ORCID: https://orcid.org/0000-0002-3271-1419)
- Chang Hoon Lee (ORCID: https://orcid.org/0000-0003-2210-0793)
- Ho Lee (ORCID: https://orcid.org/0000-0001-5573-742X)
- Hyun Ji Kim (ORCID: https://orcid.org/0000-0001-7959-2763)
- Hye Ja Lee
- Hyun Jung Byun
- Sang Gun Kim
- Mi Kyung Park (ORCID: https://orcid.org/0000-0003-4257-6799)
- Jee Young Sung
- Seung Bae Rho
Institutions
- University of Minnesota (US)
- Seoul National University (KR)
- University of Suwon (KR)
- Yonsei University (KR)
- Dongguk University (KR)
- National Cancer Center (KR)
- Minneapolis Heart Institute Foundation (US)
- Suwon Science College (KR)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2025-04-28
- DOI
- https://doi.org/10.1186/s12964-025-02182-3
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Cancer Center
- National Research Foundation of Korea
- Ministry of Education, India